Midwest CEPAC Meeting: Cardiovascular Disease, University of Missouri-St. Louis, Thursday, 26. September 2019

The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on September 26, 2019 to consider the comparative clinical effectiveness and value of additive therapies for cardiovascular disease. Interventions of interest include Xarelto® (rivaroxaban, Janssen) and Vascepa® (icosapent ethyl, Amarin). 
Cardiovascular disease defines a complex, burdensome, and highly prevalent set of conditions. Three of the major types of cardiovascular disease, coronary artery disease, peripheral artery disease, and cerebrovascular disease, result from atherosclerosis, a chronic degenerative process involving increasing buildup of plaque formed by fat- and cholesterol-based deposits. Over time, these deposits result in arterial narrowing and wall hardening, which in turn can result in angina, claudication, myocardial infarction, or stroke, among other problems. In total, cardiovascular disease is estimated to affect one-half of adults in the US, and is the leading cause of death, with approximately 850,000 deaths annually. Cardiovascular disease also imposes a substantial financial burden, with annual direct and indirect costs estimated to total $1.1 trillion.
A list of key dates for stakeholder engagement opportunities and other important information associated with the review of additive therapies for cardiovascular disease can be found on ICER's website at 

Midwest CEPAC Meeting: Cardiovascular Disease

Find more events around you
Get event recommendations based on your Facebook taste. Get it now!Show me the suitable events for meNot now